https://stockhub.co/index.php?action=history&feed=atom&title=Infant_Bacterial_Therapeutics_ABInfant Bacterial Therapeutics AB - Revision history2026-04-10T05:02:28ZRevision history for this page on the wikiMediaWiki 1.43.5https://stockhub.co/index.php?title=Infant_Bacterial_Therapeutics_AB&diff=56623&oldid=prev>Nick: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants..."2022-08-21T13:28:18Z<p>Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants..."</p>
<p><b>New page</b></p><div>== Summary<ref>Source: Yahoo Finance.</ref> ==<br />
<br />
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.<br />
<br />
== References and notes == <br />
[[Category:Thesis]]<br />
__INDEX__</div>>Nick